EORTC 1508: A phase II study of the anti-PD-L1 antibody atezolizumab, bevacizumab and acetylsalicylic acid to investigate safety and efficacy of this combination in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma
Who can take part
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
You may be able to take part in this clinical trial if you:
- recurrent advanced epithelial ovarian, fallopian tube or primary peritoneal cancer
- cancer that is platinum-resistant
- a tumour that can be safely biopsied
This is not an exhaustive list. If you're interested in participating in a clinical trial, you should speak to your doctor about what other criteria might apply.
About the trial
In cases where ovarian, fallopian tube or peritoneal cancer has come back (recurrence or relapse) and it has become resistant to platinum-based chemotherapy, new treatment strategies and new drugs are needed to better treat this disease.
This study tests a new drug both in combination with a known treatment and alone, to find out if the different combinations work better in treating the ovarian cancer and if they are safe.
The drugs involved in this trial are:
- Atezolizumab (new drug) — an ‘immunotherapy’ drug that boosts your body's own immune system in a way that may slow down or stop tumour growth.
- Bevacizumab (known drug) — a drug that stops the tumour from growing its own blood vessels, which in turn should slow the growth of the tumour itself.
- Aspirin (known drug)— a commonly used drug that may help make atezolizumab and bevacizumab work better.
If you take part in this study, you'll be randomised (placed into a treatment group by a computer) into one of three treatment groups:
- Bevacizumab alone
- Bevacizumab and atezolizumab and placebo (dummy drug)
- Bevacizumab and atezolizumab and aspirin
The information from these different groups of people will be compared to see which treatment is better.
